ImmuCell Q1 2024 Earnings Report $4.41 -0.17 (-3.71%) (As of 12/20/2024 05:51 PM ET) Earnings History ImmuCell EPS ResultsActual EPS-$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuCell Revenue ResultsActual Revenue$7.26 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuCell Announcement DetailsQuarterQ1 2024Date5/14/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptICCC Earnings History Wall Street Icon: “You must get on the right side of this thing” (Ad)I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. ImmuCell Earnings HeadlinesImmuCell Third Quarter 2024 Earnings: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023)November 16, 2024 | finance.yahoo.comImmuCell Reports Strong Sales Growth in Q3 2024November 15, 2024 | markets.businessinsider.comWall Street Icon: “You must get on the right side of this thing”I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.December 22, 2024 | InvestorPlace (Ad)ImmuCell Corporation (ICCC) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024November 13, 2024 | globenewswire.comImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024November 7, 2024 | globenewswire.comSee More ImmuCell Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email. Email Address About ImmuCellImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.View ImmuCell ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
